I don't think the markets realizes just how large the global opportunity is for the prevention of dengue fever.
The prevention market is already huge for malaria, the same will exist for dengue.
In fact, the prevention market is huge for many diseases. However, the market doesn't appear to understand that so many drugs are for prevention or keeping a disease from progression, as apposed to a 'complete cure'.
The market appears disappointed that the evidence suggests the drug is a great as a preventative, with the jury still being out in regards to the drug being an effective cure.
To wake the stock up, and get the company on the radar, a serious Joint Venture partner needs to come on board. Or perhaps a buy out or licensing deal.
Thoughts Davisite ?
Ann: Successful Phase 2 clinical trial of ISLA-101, page-88
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.59M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 65547 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 71465 | 3 |
View Market Depth
| Last trade - 09.09am 18/06/2025 (20 minute delay) ? |
| ILA (ASX) Chart |
Day chart unavailable